In the meta-analysis by Lee et al. [32], the risk of malignant melanoma was also not increased for BRCA1 [RR 0.90, 9%CI 0.16–5.07] and BRCA2 GPV carriers and their family members [RR 0.56, 95%CI 0.13–2.35]. The gene discussed is BRCA2; the disease is melanoma.